Mankind Pharma Limited has appointed Anish Vanraj Bafna as a Non-Executive Independent Director, effective August 10, 2026, with the appointment to be confirmed by members for a five-year term. The move was approved by the company’s board, which also announced that a Postal Ballot Notice will be circulated to seek member approval for the appointment. The company emphasized that the appointment is in line with regulatory requirements and governance best practices, while reinforcing its oversight framework.
Bafna brings more than three decades of experience in the healthcare and medical devices sector, including a long tenure as Chief Executive Officer and Managing Director of Healthium Medtech Limited, where he steered growth and global expansion. He currently serves as Non-Executive Chairman of Healthium. His career also spans leadership roles at Baxter International, where he held roles such as President – Japan and Regional Head – Emerging Asia, with responsibilities across India, Southeast Asia and beyond. His professional journey has taken him to markets across Vietnam, Indonesia, Malaysia, Singapore, Japan and India, highlighting a broad international perspective.
The appointment underscores Mankind Pharma’s approach to strengthening its board with seasoned industry executives who can contribute to strategic governance as the company eyes broader growth opportunities. The nomination and Remuneration Committee recommended the move, and the Postal Ballot Notice will be issued in due course for member approval. Beyond governance, the addition of an independent voice with deep global healthcare experience signals a potential boost to the company’s strategic perspectives and stakeholder confidence.
As the pharmaceutical sector continues to evolve, Mankind Pharma’s refreshed boardroom lineup reflects a pattern among industry players to bring in independent leadership with hands-on international experience. The market will be watching how this governance infusion translates into strategic execution and long-term value creation for shareholders and patients alike.